ID

32230

Descrizione

Lithium Drug-Drug Interaction Study With Lurasidone HCl; ODM derived from: https://clinicaltrials.gov/show/NCT01074073

collegamento

https://clinicaltrials.gov/show/NCT01074073

Keywords

versioni (1)
  1. 24/10/18 24/10/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

24 ottobre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Schizophrenia NCT01074073

Inglese

Eligibility Schizophrenia NCT01074073

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
Descrizione

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0036341
UMLS CUI [2]
C0036337
UMLS CUI [3]
C0036358
2. females who participate in this study:
Descrizione

Gender

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079399
are unable to have children-or-
Descrizione

Infertility

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021359
are willing to remain abstinent from day -5 until 90 days after discharge;
Descrizione

Sexual Abstinence Willing

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0036899
UMLS CUI [1,2]
C0600109
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
Descrizione

Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0036899
UMLS CUI [1,3]
C0600109
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C0009653
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
Descrizione

Antipsychotic Agents Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C0332197
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
Descrizione

Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0237442
UMLS CUI [1,4]
C3218141
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0025519
UMLS CUI [2,4]
C3218141
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0221102
UMLS CUI [3,4]
C3218141
UMLS CUI [4]
C0017178
UMLS CUI [5,1]
C0543467
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0237442
UMLS CUI [5,4]
C3218141
UMLS CUI [6,1]
C0543467
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0025519
UMLS CUI [6,4]
C3218141
UMLS CUI [7,1]
C0543467
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C0221102
UMLS CUI [7,4]
C3218141
2. positive test results within 30 days prior to the start of the study for:
Descrizione

Positive Laboratory Test Result

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1335447
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
Descrizione

Study Subject Participation Status | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
Descrizione

Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0678227
UMLS CUI [1,3]
C0151878
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0678227
UMLS CUI [2,3]
C1560305
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
Descrizione

Monoamine Oxidase Inhibitors

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0026457
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
Descrizione

Injection of depot antipsychotic agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2585377
Ritorna all'inizio della pagina

Similar models

Eligibility Schizophrenia NCT01074073

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Item
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0036358 (UMLS CUI [3])
Gender
Item
2. females who participate in this study:
boolean
C0079399 (UMLS CUI [1])
Infertility
Item
are unable to have children-or-
boolean
C0021359 (UMLS CUI [1])
Sexual Abstinence Willing
Item
are willing to remain abstinent from day -5 until 90 days after discharge;
boolean
C0036899 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male
Item
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
boolean
C0079399 (UMLS CUI [1,1])
C0036899 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0009653 (UMLS CUI [3])
Antipsychotic Agents Absent
Item
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
boolean
C0040615 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product
Item
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C3218141 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0025519 (UMLS CUI [2,3])
C3218141 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0221102 (UMLS CUI [3,3])
C3218141 (UMLS CUI [3,4])
C0017178 (UMLS CUI [4])
C0543467 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0237442 (UMLS CUI [5,3])
C3218141 (UMLS CUI [5,4])
C0543467 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0025519 (UMLS CUI [6,3])
C3218141 (UMLS CUI [6,4])
C0543467 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C0221102 (UMLS CUI [7,3])
C3218141 (UMLS CUI [7,4])
Positive Laboratory Test Result
Item
2. positive test results within 30 days prior to the start of the study for:
boolean
C1335447 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval
Item
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
boolean
C0013227 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0151878 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C1560305 (UMLS CUI [2,3])
Monoamine Oxidase Inhibitors
Item
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
boolean
C0026457 (UMLS CUI [1])
Injection of depot antipsychotic agent
Item
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
boolean
C2585377 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial